Australian (ASX) Stock Market Forum

IMM - Immutep Limited

Jump to new
A few months ago I thought I'd have a 'play' and bought $500 of this one at 5.8c, (with no research at all).
I'm going to stay on for the whole ride.......just wish I'd bought more.
 
Well that 20 or 30% has happened and its now at support levels, approx 25c. Interesting times for holders of the stock ahead.

lucifuge said:
Out of interest for PRR's long term charting history, I include the 17 year weekly chart. There is 'long past' support/resistance line of approximately 25c (which st about 19c today, is currently about 20 to 30% from hitting it). At the rate PRR is rising the relevance of this line will possibly tested sooner than later.
Click to expand...
 
Another big spike today. There must be something behind this rise ??? Anyone with any ideas ???? The company annual report doesn't seem to spotlight anything new that was not already known
For the record I don't own any shares in this stock. (I wish I did)
 
I got in at 0.11 so pretty happy with this :);)
Not sure what is driving it up TBH no doubt they might get a please explain
 
Just noticed that Prima has come out with a SPP. Does anyone have any thoughts on the pros and cons of being involved in this one. I have noticed that they have already had one back in May and another one in December last year.
 
LarryL said:
Just noticed that Prima has come out with a SPP. Does anyone have any thoughts on the pros and cons of being involved in this one. I have noticed that they have already had one back in May and another one in December last year.
Click to expand...

You have to do your own research, but as speculative stocks go, it's my pick from a wide bunch. They are about to start Phase IIb trials in the US, have news today on securing a patent in Japan. I think they have or are about to break in the Euro market. Personally, I think the potential upside is enormous. There was a segment a night or two ago on Today Tonight (or a Current Affair) on ovarian cancer and they highlighted how much more of a danger it is than breast cancer. So, PRR are working on an extremely important health product and get my vote and support for doing so. But as I say, do your own research and satisify yourself.
 
LarryL from pure technicals perspective why not wait a bit longer to see how the dust settles? We're in a win win situation, either we get a VWAP discount or 15c, whichever is lower, that's win win in my book. I would be waiting till last possible minute to pull the trigger if you are considering.

Personally I am heavily weighing the pros and cons as this is a bit risky to increase my exposure, its always been a pure speccie play for me (but conversely it held today whilst my beloved miners and energy stocks got trashed, go figure)
 
This is an article from
proactiveinvestors.com.au Thursday, October 22, 2009

Couldn't paste link as I haven't had enough posts. You can find the article on the proactiveinvestors website

"Psst, want to know one of the best performing stocks on the ASX in 2009? A tip, this is not a mining stock.

Prima BioMed (ASX: PRR), an Australian healthcare company, rocketed from $0.005 to $0.265 in October - a mere gain of 5,200% - for investors who stayed the course.

Currently, the share price is $0.185.

Prima BioMed's lead product is CVac™. It is a vaccine therapy to treat ovarian cancer administered post-surgery and post-chemotherapy to delay relapse and control metastases.

What has generated excitement is that in August, the company received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for CVac™ to proceed with a Phase IIb clinical trial in the US.

The trial, which will be conducted in of Seattle and managed out of the US, will be closely watched as will news of results filtering through.

Pfizer’s former Director of Global Medical, Ginny Raymond will oversee the pivotal clinical trial. The company said the trials will begin in the near future.

Following that trial, Prima BioMed intends to commence commercial treatment of ovarian cancer patients, beginning in Australia and New Zealand.

The prize for Prima BioMed is significant. Recent estimates put the global market for ovarian cancer treatments at US$2 billion, and expected to rise to over US$3 billion by 2010.

Importantly, for patients, and for Prima BioMed, there is a large un-met medical and market need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

Funding for these types of trials are not cheap. Here, Prima BioMed is ahead of the curve. In July, the company received funding from New York-based investment fund SpringTree Special Opportunities Fund, LP.

Springtree knew a thing or two about successful investing in the "small-cap" space. Its successful investment in NASDAQ-listed company Dendreon Corporation (NASDAQ: DNDN), applied similar technology, to Prima BioMed, to develop a vaccine treatment for prostate cancer.

Springtree likes to hedge its bets, providing a A$25.5 million convertible loan facility to Prima BioMed, doled out in 35 installments of $700,000 each, with upfront payments already made. An additional 15 million/5 year options are to be issued to Springtree.

The convertible note accrues no interest, as long as Prima BioMed does not default under the loan terms.

The funding has removed much of the financial risk, that is attached to emerging biotechnology or healthcare companies.

A NASDAQ listing down the track might also ignite greater global interest in Prima BioMed.

Prima BioMed's subsidiary company, Cancer Vac Pty Ltd, has secured a Japanese patent for peptides that mimic the MUC1 antigen. This is the key cancer antigen under development in its ovarian cancer immunotherapy program.

The wraps are high from Springtree on the prospects for Prima BioMed's CVac™, based on its due diligence. Its success with its Dendreon investment, which applied similar technology (to Prima BioMed), to developing a vaccine treatment for prostate cancer, lends comfort.

The last year has seen a heady rise in market valuation of Prima BioMed. Some fall-back is to be expected. However, the upcoming Prima BioMed clinical trials, and market need for a successful therapy, bear keeping a close eye on Prima BioMed"
 
PRR Announcement today 30 October, 2009:


Regarding Springtree funding -

"As at 29th October 2009 the note was amended to be simply a 10% discount of the average volume - weighted average price of ordinary shares in the Company for a period of 5 consecutive business days during a specified period ending on the date immediately prior the the relevant repayment date."


A much better deal for PRR.:banghead:
 
I posted the following on another forum, interested to hear anyone here's thought on how the SPP may play out.

I think we could see the SPP play out 3 ways dependent on that all important VWAP of the 5 days leading up to closure:

1. VWAP >16.5c : This I think would lead to the most people taking up the SPP, but also a lot of dumping on issue as the quick profit will be too much for most, so would most likely see a sharp drop immediately on issue.

2. VWAP 14c - 16.5 : With the market price so close to the SPP many prospective subscribers would be thinking "Why bother?" I imagine this having the lowest take up, and things keep trading as usual

3. VWAP <14c : Now this I think would be very interesting. You get a 10% discount on VWAP, and you end up with more shares than if they were issued at 15c, so I personally think would be a good buy, you end up with a lot of shares at a bargain price which is a good thing if you think this company is going places long term. However I think the fact that the price is under the maximum issue price will spook a lot of people, especially those that don't realise that if the VWAP is <15c the shares are issued at VWAP -10%. So this scenario could end up with a lower subscriber rate, and less of a sell down as it would be more attractive to the longer term holders.

Interested to hear others takes on these ideas, I may indeed have no idea what I'm on about :p

As always DYOR, not advice, etc.
Click to expand...

Personally I think I'll probably take up the SPP, and as with most will be hoping for a higher price rather than lower, but what do others think?
 
I will be taking up my entitlement.
I like the idea that New York-based investment fund SpringTree, has put their money behind PRR in this financial climate.
 
I own a small parcel of Prima and recently used a case study I had to do for one of my business courses at uni to look at the company. It's certainly still very speculative, but the press is good and I looked towards simple things like patents, intellectual property and even the recent update of the ompany website to see what they are doing. If a move near 19cents or so around SPP cut off eventuates, I'll pull the trigger then sell half straight up probably...hoping it holds onto gains. But yeah, interesting considering they've recieved funding...why do they need more capital? Erm... no idea. So, take care with this one guys. Don't put the house on it but get ready for something special if it does take flight. 50/50.
 
PRR currently in trading halt:

"In accordance with ASX Listing Rule 17.1, the directors of Prima Biomed Limited (PRR) request an immediate trading halt in the securities of the company pending an announcement to the ASX regarding the development of an oral vaccine for cervical cancer."
Click to expand...

Will be very interesting to see the contents of this announcement, some big news could send the subscription rate for the SPP very high.
 
Cross post from 'that-other-forum-that-shall-not-be-named':

There is a bit more to this than what has come out in the announcement. Indeed the announcement simply says they are beginning to research this delivery method, but comments that Martin Rogers has made to the media reveal that this may be much more advanced than starting a project from scratch.

See article on lifescientist.com.au (can't link it as unable to link in posts yet, easy enough to find in a google search)

In particular M.R.'s comments:

"The work on the basic platform science is pretty advanced and has been published, but this is the first time this has been applied to Gardasil," he said.

Rogers expects clinical trials on the vaccine to begin in around six to 12 months.
Click to expand...
 
So far it is sounding very positive. Alot of people are still uncertain because the report stated research is being undertaken, but as mentioned the project and research is alot further then it looks. Also the following quote reinforces confidence in this company.

The investment in an oral cervical cancer vaccine won't impact Prima BioMed's most advanced product, CVac, an ovarian cancer treatment.
Click to expand...

I have picked up some shares this week at what I believe is a very good price, I think not many have caught on yet, so sitting back for the ride - just my opinion.
 
Australian healthcare company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce that the Company’s Share Purchase Plan closed yesterday, Wednesday 25 November, and raised $9.6 million.
Click to expand...

Very nice result considering statements to the media that they were looking to raise ~$5 Million :cool:
 
Also in today's AGM presentation the figure raised from the SPP was revised up to $11.25M

Shares have been issued to most holders by the looks (mine appeared this afternoon at some stage) which has led to a fair bit of trade just above the issue price, presumably from those selling straight up for a quick $1k.
 
Top